Ciclosporin - Sigmoid Pharma

Drug Profile

Ciclosporin - Sigmoid Pharma

Alternative Names: AlloCol; Cyclosporin - Sigmoid Pharma; Cyclosporine - Sigmoid Pharma; Cyclosporine A - Sigmoid Pharma; CyCol; CyCron; CyLow; Oral cyclosporine - Sigmoid Pharma

Latest Information Update: 12 Apr 2016

Price : $50

At a glance

  • Originator Sigmoid Pharma
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transplant rejection
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Graft-versus-host disease; Transplant rejection; Ulcerative colitis

Highest Development Phases

  • Phase II Ulcerative colitis
  • Phase I Crohn's disease; Graft-versus-host disease; Psoriasis; Transplant rejection

Most Recent Events

  • 29 Sep 2014 Cyclosporine licensed to Pendopharm in Canada
  • 08 Sep 2014 Sigmoid Pharma completes enrolment in a phase I trial in Healthy volunteers in United Kingdom (NCT02130414)
  • 31 Jul 2014 Sigmoid Pharma initiates enrolment in a phase I trial in Healthy volunteers in United Kingdom (NCT02130414)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top